EQRx, known as the "TEMU" of the pharmaceutical industry, has been acquired by Revolution Medicines,posing a risk of "returns" for Chinese innovative drugs.
Pharmaceutical company EQRx and a life science-focused special purpose acquisition company (SPAC), CM Life Sciences III, have signed a definitive business combination agreement worth up to $1.8bn.